Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how effective rituximab and acalabrutinib are when
given as a combination treatment for newly diagnosed B cell post transplant
lymphoproliferative disorder (PTLD). Currently there is no approved therapy for PTLD.
Rituximab alone is commonly used and works in some cases, but not others. In addition,
participants with PTLD have trouble tolerating therapies with large amounts of side effects
due to their health conditions and medications for their transplant. Due to these reasons the
study team is looking for a new treatment with novel targeted agents in order to improve
outcomes and to minimize toxicity.
Based on emerging data of clinical efficacy of acalabrutinib in B cell malignancies and an
unmet need for novel therapies in PTLD, this study will investigate the use of rituximab and
acalabrutinib in participants with newly diagnosed B cell PTLD.